1. COVAX - OMS. 
    https://www.gavi.org/covax-facility
  2. Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination. Samantha Lane, et al. MedRxiv. December 21, 2021.
    https://doi.org/10.1101/2021.12.20.21268102
  3. Report 48: The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant. Hogan A, et al. Imperial College London. December 15, 2021.
    https://doi.org/10.25561/93034
  4. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. Alejandro Jara, Ph.D. et al. The New England Journal of Medicine. September 02, 2021.
    https://doi.org/10.1056/NEJMoa2107715
  5. Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. Matthew S. Krantz et al. JAMA Intern Med. July 26, 2021.
    https://doi.org/10.1001/jamainternmed.2021.3779
  6. Myocarditis After BNT162b2 and mRNA-1273 Vaccination. Kathryn F. Larson, et al. AHA Journals. June 16, 2021. https://doi.org/10.1161/CIRCULATIONAHA.121.055913
  7. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Manish Sadarangani et al. Nature Reviews Immunology. July 01, 2021.
    https://doi.org/10.1038/s41577-021-00578-z
  8. COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room. Piero Olliaro et al. The Lancet. July 01, 2021.
    https://doi.org/10.1016/S2666-5247(21)00069-0
  9. Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. Weilin Zhou & Wei Wang. Nature. June 09, 2021.
    https://doi.org/10.1038/s41392-021-00644-x
  10. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. David S. Khoury et al. Nat Med. May 17, 2021.
    https://doi.org/10.1038/s41591-021-01377-8
  11. Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster. Kai Wu et al. medRxiv. May 06, 2021.
    https://doi.org/10.1101/2021.05.05.21256716
  12. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. Mark G. Thompson et al. Centers for Disease Control and Prevention. April 02, 2021.
    http://dx.doi.org/10.15585/mmwr.mm7013e3
  13. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. Shabir A. Madhi, Ph.D. et al. NEJM Group. March 16, 2021. 
    https://doi.org/10.1056/NEJMoa2102214
  14. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. Lindsey R. Baden et al. The New England Journal of Medicine. February 04, 2021. 
  15. https://doi.org/10.1056/NEJMoa2035389
  16. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Denis Y Logunov et al. THE LANCET. February 02, 2021. 
    https://doi.org/10.1016/S0140-6736(21)00234-8
  17. Draft landscape and tracker of COVID-19 candidate vaccines. WHO. January 22, 2021.
    https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
  18. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Kate M. Bubar et al. Science. January 21, 2021. 
    https://doi.org/10.1126/science.abe6959
  19. Looking beyond COVID-19 vaccine phase 3 trials. Jerome H. Kim et al. Nat Med. January 19, 2021.
    https://doi.org/10.1038/s41591-021-01230-y
  20. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Prof Shengli Xia, BSc et al. The Lancet. October 15, 2020. 
    https://doi.org/10.1016/S1473-3099(20)30831-8
  21. Facial Masking for Covid-19 — Potential for “Variolation” as We Await a Vaccine. Monica Gandhi, M.D., M.P.H., and George W. Rutherford, M.D. The New England Journal of Medicine. September 08, 2020. 
    https://doi.org/10.1056/NEJMp2026913
  22. Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. Ali J.Marian. ELSEVIER. Febrero, 2021. 
    https://doi.org/10.1016/j.carpath.2020.107278
  23. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Denis Y Logunov, DSc, et al. September 04, 2020.
    https://doi.org/10.1016/S0140-6736(20)31866-3
  24. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. Kizzmekia S. Corbett, et al. NEJM. July 28, 2020. https://doi.org/10.1056/NEJMoa2024671
  25. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Pedro M Folegatti, MSc, et al. THE LANCET. July 20, 2020. 
    https://doi.org/10.1016/S0140-6736(20)31604-4
  26. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. Lisa A. Jackson, et al. NEJM. July 14, 2020.
  27. https://doi.org/10.1056/NEJMoa2022483
  28. Can existing live vaccines prevent COVID-19?. Konstantin Chumakov, Christine S. Benn, Peter Aaby, Shyamasundaran Kottilil, Robert Gallo. Science  12 Jun 2020: Vol. 368, Issue 6496, pp. 1187-1188.
    https://doi.org/10.1126/science.abc4262